Who mentions $QNTM most on Surfaced?

$QNTM – A Biotech Story Gaining Momentum Strong intraday reversal from $3.60 → $4.80, Clear trend shift after mid-day Quantum BioPharma Ltd. ($QNTM) is starting to transition from a speculative microcap into a multi-catalyst biotech opportunity. The company has strengthened its financial position, with a runway extending into 2028 — a key advantage in a sector often challenged by dilution. At the core is Lucid-MS, a drug candidate targeting the root cause of multiple sclerosis, now progressing toward Phase 2 trials. Backed by collaboration with Massachusetts General Hospital, the program is moving into a critical stage of development. Beyond its pipeline, $QNTM also brings a unique angle through Unbuzzd, a clinically validated product with potential commercialization and IPO upside. While risks remain, the combination of clinical progress, improving financials, and multiple catalysts suggests the company is entering a more execution-driven phase. A name worth watching as the story continues to evolve. Paid promotion #advertisement , got paid for the content. Not a financial advice Disclaimer: https://t.co/zhpDByazPj

Open on X

@investmentguru_Mar 27, 2026 · 6:35 PM

$QNTM + 22 % now

Open on X

@investmentguru_Mar 27, 2026 · 5:41 PM

$QNTM almost 15% up

Open on X

@investmentguru_Mar 27, 2026 · 3:39 PM

$QNTM is starting to look very interesting here. Quantum BioPharma Ltd. is quietly transitioning from a speculative microcap into a multi-catalyst biotech story: •Runway into 2028 •Phase 2 MS trial approaching (Lucid-MS) •Backed by collaboration with Massachusetts General Hospital •Unbuzzd now clinically validated with potential IPO upside Paid promotion, #advertisement @TheFlowShark See disclaimer in original post below 👇

Open on X

@investmentguru_Mar 27, 2026 · 2:01 PM

The market still treats $QNTM like a risky microcap. But reality is shifting: ✔️ Clinical progress (Phase 2 incoming) ✔️ Real product with validation ✔️ Potential IPO + royalties ✔️ Stronger balance sheet These are the setups that go from quiet → explosive. Paid promotion, # advertisements Please see disclaimer in original post below 👇

Open on X

@investmentguru_Mar 27, 2026 · 1:33 PM

$QNTM is stacking catalysts FAST: •Phase 2 MS trial getting ready (PI appointed) •Unbuzzd now peer-reviewed & validated •$3.75M fresh capital raised •Runway into 2028 This is no longer just a story stock… paid promotion, see disclaimer in original post below 👇

Open on X

@investmentguru_Mar 27, 2026 · 1:16 PM

$QNTM https://t.co/20d0uXFcPm

Open on X

@investmentguru_Mar 27, 2026 · 1:14 PM

$QNTM – Strengthening the Foundation, Building the Upside. Quantum BioPharma just delivered a key milestone update with its 2025 audited results — and the tone is clearly shifting toward execution and monetization. Balance Sheet Improving •Cash + digital assets: $11.3M USD •No going concern → runway projected through January 2028 •Operating expenses: $15.3M (↓ 5% YoY) •Payables cut by ~50% •Stronger access to capital markets (convertibles, loans, asset monetization) This is a big step in de-risking the story Pipeline Progress – Lucid-MS (MS Program) •Phase 1 toxicity studies: completed, no major side effects •Oral formulation → easier administration vs injections •Phase 2 IND expected H1 2026 •Collaboration with Massachusetts General Hospital Potential first-in-class neuroprotective approach in multiple sclerosis Paid promotion, #advertisement @TheFlowShark Disclaimer: https://t.co/SwIfiK0OJZ https://t.co/BPY8JOlOEB… https://t.co/hSzXJPo9Ys

Open on X

@investmentguru_Mar 27, 2026 · 11:59 AM

$QNTM – From Speculative Microcap to Multi-Catalyst Biotech Story Unfolding Over the past week, $QNTM has quietly delivered a series of developments that signal a clear transition from hype to execution — and the market hasn’t fully priced it in yet. First, the financial foundation has improved significantly. The company now holds approximately $11.3M in cash and digital assets, with a projected runway extending into 2028. On top of that, management has reduced payables by nearly 50% and lowered operating expenses year-over-year. In a sector where most microcap biotechs struggle with survival and constant dilution, this matters. A stronger balance sheet gives $QNTM the ability to focus on execution rather than emergency financing. Now to the core asset — Lucid-MS. Lucid-MS is being developed to target demyelination in multiple sclerosis, addressing the root cause rather than just managing symptoms. It’s also an oral therapy, which gives it a major advantage over current treatments that rely on injections or infusions. Recent progress has been meaningful: •Phase 1 trials and toxicity studies completed with no major safety concerns •IND filing for Phase 2 expected in H1 2026 •Dr. Salvatore Napoli appointed as Principal Investigator for Phase 2 That last point is critical — you don’t bring in trial leadership unless you are preparing to execute. This signals that $QNTM is entering a key value inflection stage. In parallel, the company is working with researchers at Massachusetts General Hospital, where early-stage patient imaging is already underway. This adds a layer of scientific validation that many microcaps lack. But what makes $QNTM unique is that it’s not a one-dimensional biotech. The company also has a near-term monetization angle through its consumer product, Unbuzzd. Unbuzzd just achieved a major milestone: its clinical trial was published in a peer-reviewed journal, confirming that it can: •Accelerate alcohol metabolism •Reduce intoxication effects •Improve mental clarity This is a rare combination — a product with both clinical backing and consumer appeal. Even more interesting: •$QNTM owns roughly 20% of the Unbuzzd business •It receives royalty revenue (7% up to $250M) •There is potential for an IPO, which could unlock non-dilutive capital On top of that, Health Canada has already approved Qlarity, opening a commercial pathway in Canada. And recently, the company closed a $3.75M financing tranche, further strengthening its ability to execute upcoming milestones. When you step back, the full picture becomes clear: $QNTM now has: •A progressing MS drug entering Phase 2 •A clinically validated consumer product with monetization potential •Improved financial stability with extended runway •Multiple near-term catalysts •Optional upside from a legal case against major financial institutions Yet, it is still being priced like a high-risk, early-stage microcap. That disconnect is where opportunity lives. This is exactly the type of setup where asymmetric upside is created. The market often ignores these names during accumulation phases… and then reprices them aggressively when catalysts start hitting. Paid #advertisement got paid for this promotion Disclaimer: https://t.co/zhpDBya1ZL DYOR, not a financial advice. Other biotech- $BIIB $DNLI $ALKS $ACIU

Open on X

$QNTM

$QNTM

About this stock

Frequently asked

Related stocks